SRY-box transcription factor 4 (SOX4) mRNA (SOX4 mRNA)

SRY-box transcription factor 4 (SOX4) mRNA encodes a member of the SOX family of transcription factors, which are essential for embryonic development, including heart and central nervous system morphogenesis [UniProt Q06945]. In oncology, SOX4 mRNA is frequently overexpressed and acts as a master regulator of the epithelial-mesenchymal transition (EMT), promoting tumor metastasis and stemness [PMID: 24403100]. It also plays a role in B-cell differentiation and survival, and its dysregulation is linked to various leukemias and solid tumors [NCBI Gene ID: 6659]. Therapeutic targeting of SOX4 mRNA typically involves antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) designed to induce transcript degradation or block translation [PMID: 31320884]. These approaches aim to downregulate SOX4 protein levels, thereby inhibiting oncogenic signaling pathways and sensitizing cancer cells to apoptosis. While no SOX4-targeted therapies are currently FDA-approved, experimental siSOX4 and ASO-SOX4 molecules have shown efficacy in preclinical models by suppressing tumor growth and invasion [PMID: 23418319]. Consequently, SOX4 mRNA represents a high-priority target for the development of precision medicines against aggressive and metastatic malignancies.

Other names

SRY-box 4 mRNASOX4 transcriptEVI16 mRNA

Antisense inhibition and RNA interference leading to mRNA degradation or translational repression.